MIMEDX Provides AXIOFILL® Update & Reiterates 2023 Full

Receipt of FDA Warning Letter for AXIOFILL Classification; Not Related to Safety Request for Designation for AXIOFILL Submitted to FDA and Currently...

Related Keywords

United States , Matt Notarianni , Josephh Capper , Public Health Service , Mimedx Group Inc , Drug Administration , Exchange Commission , Nasdaq , Not Related , Currently Under , Sales Growth , High Teens , Fourth Quarter Adjusted , Medx Group , United States Food , Warning Letter , Human Cell , Tissue Based Product , Executive Officer , Private Securities Litigation Reform Act , Nasdaq Mdxg , Mimedx Group , Nc ,